Octavio Marquez

Diebold Nixdorf CEO Octavio Marquez buys 1,250 shares for $99,333.82; cluster buy with 2 other insiders in 14 days

Octavio Marquez, President and CEO, executed 2 separate purchases totaling 1,250 shares for $99,333.82 at a blended average price of $79.47 on 2026-05-26 and 2026-05-27. This filing joins a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting broader management alignment around current valuations. Marquez's same-ticker history at DBD shows 3 of 5 prior buys were well-timed at the 90-day mark (with positive subsequent returns), establishing a meaningful pattern of transaction timing at this specific company. The current stock price of $78.03 is 12.4% below the 52-week high and down 5.2% over 30 days, providing context for the timing and scale of this $99.3K acquisition by the chief executive.

DBD CEO Marquez buys 1,690 shares for $69,018.92; stock down 11.8% in 30 days; cluster buy pattern.

Marquez Octavio, President and CEO, purchased 1,690 shares (2 separate transactions totaling $69,018.92) at an average price of $40.84 on 2024-11-12. The stock has declined 11.8% over the prior 30 days and currently trades at $40.51, near the transaction price. Critically, Diebold Nixdorf reported a net loss of $22.4M in its latest quarter and experienced annual revenue decline of -11.4%; the company remains unprofitable on a full-year basis, creating headwinds regardless of insider sentiment. The filing coincides with a cluster buy pattern in which 2 other insiders also purchased within the past 14 days, suggesting coordinated confidence at current levels. Historical context at this ticker shows Marquez has executed 5 prior buys at DBD, with 3 of 5 well-timed at the 90-day mark, though the most recent transaction-adjacent data point (30-day return post-purchase) shows the prior August buy generated +9.7%, offsetting some of the recent near-term weakness.

CEO Marquez Octavio buys 1,100 shares of DBD at $37.34; stock down 15.2% from 52-week high; company posted negative full-year earnings.

Marquez Octavio, President and CEO, purchased 1,100 shares at $37.34 on 2024-08-09, bringing his holdings to 135,774 shares. The purchase occurs as DBD trades -15.2% from its 52-week high ($44.60) and -4.0% over the past 30 days. The company's fundamentals are challenged: full-year net income was negative, annual revenue contracted -11.4%, and the trailing P/E of 6.87 reflects a deeply depressed valuation. Historically, Marquez's prior 5 buys at DBD show mixed timing—3 of 5 achieved positive 90-day returns—but his cross-ticker track record of 8 prior buys averaged +16.4% over 90 days with a 62.50% win rate. The open-market purchase of a modest stake (1.1K shares, +0.8% of existing holdings) by the CEO during a period of negative earnings and revenue decline warrants attention to whether this reflects conviction in a turnaround or simply routine capital deployment.